|
Detectable mutations precede late myeloid neoplasia in aplastic anemia |
Feb 2021 |
Haematologica |
Aplastic Anemia |
|
Luspatercept in the treatment of lower-risk myelodysplastic syndromes |
Jan 2021 |
Future Oncology (London, England) |
Myelodysplastic Syndromes (MDS) |
|
Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options |
Jan 2021 |
Cancer Management and Research |
Myelodysplastic Syndromes (MDS) |
|
Author Correction: Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? |
Jan 2021 |
Leukemia |
Myelodysplastic Syndromes (MDS) |
|
Implication of PIGA genotype on erythrocytes phenotype in Paroxysmal Nocturnal Hemoglobinuria |
Jan 2021 |
Leukemia |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
How I Treat Paroxysmal nocturnal hemoglobinuria |
Jan 2021 |
Blood |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes |
Jan 2021 |
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
|
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes |
Jan 2021 |
Journal of clinical oncology: official journal of the American Society Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
|
Treatment options for lower-risk myelodysplastic syndromes. Where are we now? |
Jan 2021 |
Therapeutic Advances in Hematology |
Myelodysplastic Syndromes (MDS) |
|
Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management" |
Jan 2021 |
American Journal of Hematology |
Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
